BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED

Bloomage BioTechnology Corporation Limited

688363

CNE100003NL9

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
60.51 ^CNY	+0.98%		+12.96%	-9.59%

Apr. 02	Tranche Update on Bloomage BioTechnology Corporation Limited's Equity Buyback Plan announced on August 17, 2023.	CI
Feb. 29	Bloomage Biotech Names CFO	MT

Tranche Update on Bloomage BioTechnology Corporation Limited's Equity Buyback Plan announced on August 17, 2023.

April 01, 2024

From August 17, 2023 to March 31, 2024, the company has repurchased 3,040,219 shares, representing 0.63% for CNY 203.98 million. With this, the company has completed the repurchase of 3,040,219 shares, representing 0.63% for CNY 203.98 million under the buyback announced on August 17, 2023.

Latest news about Bloomage BioTechnology Corporation Limited

Tranche Update on Bloomage BioTechnology Corporation Limited's Equity Buyback Plan announced on August 17, 2023.	Apr. 01	CI
Bloomage Biotech Names CFO	Feb. 28	MT
Bloomage Biotechnology's 2023 Profit Falls 39.5%; Misses EPS Estimates	Feb. 28	MT
Bloomage BioTechnology Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Bloomage BioTechnology Corporation Limited Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Bloomage Buys Back 8.4 Million Yuan Shares	23-10-05	MT
Bloomage BioTechnology Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Bloomage BioTechnology Corporation Limited announces an Equity Buyback for CNY 300 million worth of its shares.	23-08-17	CI
Bloomage BioTechnology Corporation Limited authorizes a Buyback Plan.	23-08-16	CI
Chinese company earnings reveal lopsided economic recovery	23-05-10	RE
Bloomage BioTechnology Corporation Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Bloomage Biotech Showcases Cutting-Edge Bioactive Ingredients at International Consumer Products Expo, Expands Global Reach	23-04-18	CI
Bloomage BioTechnology Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Yongtaiyun Chemical Logistics to Buy Local Chemical Producer For 50 Million Yuan	23-02-13	MT
Bloomage BioTechnology Corporation Limited Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Bloomage BioTechnology Corporation Limited(XSSC:688363) added to S&P Global BMI Index	22-09-19	CI
Bloomage Biotechnology to Absorb, Merge With Subsidiary	22-08-30	MT
Bloomage BioTechnology Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-07-20	CI
Bloomage BioTechnology Corporation Limited(SHSE:688363) dropped from Shanghai Stock Exchange Health Care Sector Index	22-06-10	CI
Bloomage BioTechnology Corporation Limited Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-25	CI
Bloomage BioTechnology Corporation Limited, entered into a property rights transaction contract to acquire 51% of Beijing Yierkang Bioengineering Co., Ltd., for CNY 233 million.	22-04-19	CI
Bloomage BioTechnology Corporation Limited(XSSC:688363) added to FTSE All-World Index	22-03-21	CI
Bloomage BioTechnology Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-25	CI
Bloomage BioTechnology Corporation Limited(SHSE:688363) added to Shanghai Stock Exchange 180 Value Index	21-12-13	CI
Bloomage BioTechnology Corporation Limited(SHSE:688363) added to SSE 180 Index	21-12-13	CI

Chart Bloomage BioTechnology Corporation Limited

Duration

Period

Chart Bloomage BioTechnology Corporation Limited

More charts

Company Profile

Bloomage Biotechnology Corp Ltd is a China-based company mainly engaged in the research and development (R&D), production and sales of hyaluronic acid and other bioactive products. The Company's products include raw material products, medical end products, functional skin care products and functional foods. The raw material products include a series of bioactive products with hyaluronic acid as the core, which are widely used in the fields of drugs, medical devices, cosmetics, functional food and general food. The medical end products are divided into medical beauty and medicine, including ophthalmic viscoelastics, medical lubricants, soft tissue fillers, medical skin protectors and others. The functional skin care products include lotion, cream, facial mask, hand mask and others. The functional foods include hyaluronic acid water, hyaluronic acid food and others.

Sector

Pharmaceuticals

Calendar

2024-04-29 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Bloomage BioTechnology Corporation Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

60.51 CNY

Average target price

83.72 CNY

Spread / Average Target

+38.35%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED	-9.59%	3.98B
CSL LIMITED	-4.06%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.97%	39.82B
UCB	+56.59%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-14.82%	15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-8.82%	11.95B
INCYTE CORPORATION	-16.29%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-41.58%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+6.14%	8.71B
INNOVENT BIOLOGICS, INC.	-7.02%	8.12B

Biopharmaceuticals

Bloomage BioTechnology Corporation Limited

Equities

688363

CNE100003NL9

Pharmaceuticals

Tranche Update on Bloomage BioTechnology Corporation Limited's Equity Buyback Plan announced on August 17, 2023.

EPS Revisions